Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Return on Equity

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's return on equity stands at 64.01%. That is above the Healthcare sector average of -75.84%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A sits higher the Healthcare benchmark (-75.84%) with a ROE of 64.01%. That is roughly 184.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 64.01% for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's ROE evolved across reporting periods, while the comparison chart places FBIOP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's reading of 64.01% (sector avg -75.84%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.